• Trip Reports Moderator: M!$ter-ED

2f-nendck trip Report 50mg

Mindtraveller87

Greenlighter
Joined
Dec 20, 2015
Messages
22
Location
Zaandam
Trip Report — 50 mg 2f-nendck pellet


Who:
Male, 38 years old, 71 kg
Setting: Alone at home. Had one beer earlier and smoked some weed.


T+0 — 01:39
Took one pellet with cola.


T+30 min
Didn’t feel much yet, so I smoked a bit of weed. After a few hits, the effects started coming up fast.


T+45 min
I was working on a beat, but I couldn’t focus anymore. Strong double vision, vertigo, and an urge to lie down. I felt some panic because it hit harder than expected, even with tolerance. The beer and weed combo was a bad match.


T+1 h
Moved a mattress to the living room so I could lie down near my girlfriend. I felt anxious and being near her helped. When I closed my eyes, it felt like I was falling from a great height, followed by an adrenaline spike. This compound seemed to increase anxiety more than other dissociatives I’ve tried.


T+1 h 15 min
I turned on my go-to remedy: the Ambient Soothes playlist. Slowly, a sense of stillness came over me.

With closed eyes, I saw what felt like a crowded room full of people. This was very different from the womb-like walls I normally see in deep dissociative meditation. Some faces looked dark or demonic, and I had a fear of negative entities entering me. I don’t actually believe in ghosts, but the experience felt very real in the moment.


T+1 h 30 min
Time started flying. For the first time, I saw what felt like an entity taking shape in front of me. When I opened my eyes, it disappeared.

The double vision seemed to intensify the meditation visuals. The synesthesia was strong; sound almost directed what I saw. Some parts felt mystical, but there was also a darker horror-like edge, with evil faces and looping negative thoughts. I kept breathing through it and focusing on the ambient music.

Songs I’ve known for years suddenly opened up in completely new ways.

T+2 h
I entered a deep meditative state. I saw what felt like an astral projection, but not as a light body — more like digital pixels leaving my body and forming another version of me.

I also had the familiar feeling that I was only an avatar inside the mind of a greater being. I tried to see through its eyes, but couldn’t make much out. I saw different people and wondered if they were past-life images or just illusions.

T+2 h 30 min
My girlfriend woke up, so I got up quickly and let her sleep on the mattress. I finished my joint and tried to understand what had just happened.

T+3 h
Still slightly in the zone from the weed, but no longer immobilized. I did some light tasks like video editing and connecting pedals to my electric piano.

T+4 h
It was getting light outside, so I got ready for bed. I turned on Ambient Soothes again and let myself drift into sleep.

Summary
Unexpectedly strong experience, around +++ intensity.

Positive: strong synesthesia, vivid visuals, deep meditation, powerful music connection, positive afterglow the next day.
Negative: anxiety, double vision, vertigo, fear, darker visuals, and looping negative thoughts.
 
Thanks @Mindtraveller87

Pharmacodynamics​

2F-NENDCK is presumed to function primarily as a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, binding to the phencyclidine (PCP) site within the receptor's ion channel pore, a mechanism characteristic of the arylcyclohexylamine class of dissociatives.<a href="https://grokipedia.com/page/2f_nendck#ref-4"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-4">[4]</a> This action is inferred from its structural similarity to ketamine and related analogs like 2-fluorodeschloroketamine (2-FDCK), for which behavioral studies in rodents demonstrate full substitution in ketamine-trained drug discrimination paradigms, indicating comparable pharmacodynamic profiles.<a href="https://grokipedia.com/page/2f_nendck#ref-6"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-6">[6]</a> No direct in vitro binding affinity or functional assays have been reported for 2F-NENDCK itself, and potency is presumed to be similar to or potentially greater than that of ketamine due to the 2-fluoro substitution on the phenyl ring, which may enhance lipophilicity and site occupancy in arylcyclohexylamine analogs.<a href="https://grokipedia.com/page/2f_nendck#ref-7"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-7">[7]</a>In addition to NMDA antagonism, 2F-NENDCK may exhibit affinity for other targets based on analogies to ketamine, including agonism at sigma-1 receptors, which could contribute to neuroprotective and mood-modulating effects.<a href="https://grokipedia.com/page/2f_nendck#ref-8"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-8">[8]</a> It is also likely to inhibit dopamine reuptake, potentially via interactions with the dopamine transporter (DAT), as observed with ketamine at clinically relevant concentrations.<a href="https://grokipedia.com/page/2f_nendck#ref-9"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-9">[9]</a> Furthermore, modulation of cholinergic systems through non-competitive inhibition of muscarinic acetylcholine receptors may play a role, accounting for some anticholinergic side effects seen in dissociative anesthetics.<a href="https://grokipedia.com/page/2f_nendck#ref-10"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-10">[10]</a>Structure-activity relationship (SAR) studies of arylcyclohexylamines indicate that the 2-fluoro phenyl substitution enhances binding at the PCP site relative to non-halogenated analogs by improving electron-withdrawing properties and steric fit within the channel, while the N-ethyl group on the amine may slightly reduce potency compared to N-methyl but still maintains high affinity overall when combined with the fluoro moiety, as seen in PCE (N-ethylphenylcyclohexylamine) derivatives.<a href="https://grokipedia.com/page/2f_nendck#ref-11"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-11">[11]</a> These modifications distinguish 2F-NENDCK from parent PCE analogs, potentially yielding greater NMDA antagonistic efficacy.<a href="https://grokipedia.com/page/2f_nendck#ref-12"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-12">[12]</a> All pharmacodynamic insights for 2F-NENDCK rely on structural analogies and preclinical data from related compounds, as no human or direct in vitro studies exist as of 2024.<a href="https://grokipedia.com/page/2f_nendck#ref-4"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-4">[4]</a>

Pharmacokinetics​

2F-NENDCK, also known as 2-fluorodeschloro-N-ethyl-ketamine, is administered recreationally via oral, intranasal, and intramuscular routes, with insufflation being common due to its similarity to ketamine use patterns. As of 2024, no direct pharmacokinetic data are available for 2F-NENDCK; all information is inferred from structural analogies to ketamine and limited user reports.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a> Based on these analogies, oral administration is expected to exhibit low bioavailability due to extensive first-pass hepatic metabolism, while intranasal and intramuscular routes likely achieve higher absorption. Onset of effects is anticipated to vary by route, potentially similar to ketamine (e.g., 5-30 minutes for intranasal or intramuscular).<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>Metabolism of 2F-NENDCK is expected to occur primarily in the liver through cytochrome P450 enzymes, though specific isoforms remain unidentified. The main biotransformation pathway is presumed to involve N-dealkylation, yielding an active metabolite analogous to norketamine (e.g., 2-fluorodeschloro-norketamine), as seen in ketamine metabolism via CYP3A4 and CYP2B6. Additional minor metabolites may include hydroxylated and glucuronidated forms, with structural modifications like fluorine substitution potentially altering metabolic rates compared to ketamine. The elimination half-life is unknown but may be similar to ketamine's 2-3 hours based on arylcyclohexylamine analogs.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>Total duration of effects is reported by users to last 4-6 hours, exceeding ketamine's typical 1-hour insufflated duration, with aftereffects persisting up to 12 hours.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a> Excretion is expected to occur mainly via renal and biliary routes, primarily as conjugated metabolites, though exact proportions are unknown. In toxicological screening, 2F-NENDCK and its metabolites are detectable in urine and blood using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS), with persistence estimated at 24-48 hours post-administration, depending on dose and individual factors; hair analysis may extend detection windows for chronic exposure. The lack of direct data underscores uncertainties in potency, toxicity, and interactions, particularly given its detection in illicit samples as of 2024.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a><a href="https://grokipedia.com/page/2f_nendck#ref-2"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-2">[2]</a>

Effects and Uses​

Subjective Effects​

The subjective effects of 2F-NENDCK, a novel arylcyclohexylamine dissociative, are primarily reported through anecdotal user accounts from harm reduction communities, as formal clinical studies are lacking. These effects resemble those of ketamine but are often described as more intense and prolonged, with a faster onset, stronger visual distortions, and greater disorientation, attributed to its presumed NMDA receptor antagonism.<a
Users report mild euphoria in some instances, often accompanying a stimulating body high that can lead to increased energy and prolonged wakefulness.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a> Dissociation from the body and mind is a core positive experience, sometimes escalating to a "k-hole"-like state of complete numbness and detachment, described as more immersive than with ketamine.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a> Strong visual distortions, including colorful hallucinations, contribute to a recreational appeal, with some noting serotonergic qualities enhancing the sensory experience.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>

Neutral Effects​

Dissociation manifests as a separation of mind from body, often without deep introspection or emotional warmth seen in ketamine.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a> Time dilation and cognitive disorientation are common, impairing memory and spatial awareness during the experience.<a href="https://grokipedia.com/page/2f_nendck#ref-3"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-3">[3]</a> Sedation varies, with some users feeling energized rather than heavily sedated.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>

Negative Effects​

Anxiety and paranoia can emerge, particularly during intense dissociation, alongside loss of motor control leading to coordination difficulties or falls.<a href="https://grokipedia.com/page/2f_nendck#ref-3"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-3">[3]</a> Nausea is frequently reported, sometimes accompanied by vomiting, and a pronounced hangover with fatigue persists into the next day.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a> At higher doses, delirium-like states with vivid auditory hallucinations and total loss of consciousness may occur, increasing risks of injury.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>Effects are highly dose-dependent, with low doses (starting below typical ketamine amounts of 20-175 mg, often as small "bumps" due to greater potency) producing stimulation and mild dissociation, while higher doses (undocumented but risking overdose) induce full "holing" with anesthesia-like immobility.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a><a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a> Compared to 2F-DCK, 2F-NENDCK is reported as more recreational and stimulating; relative to ketamine or MXE analogs, it offers less euphoria but stronger, quicker-plateauing intoxication.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>The total duration is typically 4-6 hours, longer than ketamine's profile, with a rapid onset (faster than ketamine) peaking within the first 1-2 hours and lingering aftereffects.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a><a href="https://grokipedia.com/page/2f_nendck#ref-3"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-3">[3]</a>As a novel substance first identified in 2022, 2F-NENDCK has no documented therapeutic research or approved medical uses.<a href="https://grokipedia.com/page/2f_nendck#ref-1"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-1">[1]</a>
 
Thanks @Mindtraveller87

Pharmacodynamics​

2F-NENDCK is presumed to function primarily as a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, binding to the phencyclidine (PCP) site within the receptor's ion channel pore, a mechanism characteristic of the arylcyclohexylamine class of dissociatives.<a href="https://grokipedia.com/page/2f_nendck#ref-4"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-4">[4]</a> This action is inferred from its structural similarity to ketamine and related analogs like 2-fluorodeschloroketamine (2-FDCK), for which behavioral studies in rodents demonstrate full substitution in ketamine-trained drug discrimination paradigms, indicating comparable pharmacodynamic profiles.<a href="https://grokipedia.com/page/2f_nendck#ref-6"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-6">[6]</a> No direct in vitro binding affinity or functional assays have been reported for 2F-NENDCK itself, and potency is presumed to be similar to or potentially greater than that of ketamine due to the 2-fluoro substitution on the phenyl ring, which may enhance lipophilicity and site occupancy in arylcyclohexylamine analogs.<a href="https://grokipedia.com/page/2f_nendck#ref-7"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-7">[7]</a>In addition to NMDA antagonism, 2F-NENDCK may exhibit affinity for other targets based on analogies to ketamine, including agonism at sigma-1 receptors, which could contribute to neuroprotective and mood-modulating effects.<a href="https://grokipedia.com/page/2f_nendck#ref-8"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-8">[8]</a> It is also likely to inhibit dopamine reuptake, potentially via interactions with the dopamine transporter (DAT), as observed with ketamine at clinically relevant concentrations.<a href="https://grokipedia.com/page/2f_nendck#ref-9"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-9">[9]</a> Furthermore, modulation of cholinergic systems through non-competitive inhibition of muscarinic acetylcholine receptors may play a role, accounting for some anticholinergic side effects seen in dissociative anesthetics.<a href="https://grokipedia.com/page/2f_nendck#ref-10"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-10">[10]</a>Structure-activity relationship (SAR) studies of arylcyclohexylamines indicate that the 2-fluoro phenyl substitution enhances binding at the PCP site relative to non-halogenated analogs by improving electron-withdrawing properties and steric fit within the channel, while the N-ethyl group on the amine may slightly reduce potency compared to N-methyl but still maintains high affinity overall when combined with the fluoro moiety, as seen in PCE (N-ethylphenylcyclohexylamine) derivatives.<a href="https://grokipedia.com/page/2f_nendck#ref-11"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-11">[11]</a> These modifications distinguish 2F-NENDCK from parent PCE analogs, potentially yielding greater NMDA antagonistic efficacy.<a href="https://grokipedia.com/page/2f_nendck#ref-12"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-12">[12]</a> All pharmacodynamic insights for 2F-NENDCK rely on structural analogies and preclinical data from related compounds, as no human or direct in vitro studies exist as of 2024.<a href="https://grokipedia.com/page/2f_nendck#ref-4"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-4">[4]</a>

Pharmacokinetics​

2F-NENDCK, also known as 2-fluorodeschloro-N-ethyl-ketamine, is administered recreationally via oral, intranasal, and intramuscular routes, with insufflation being common due to its similarity to ketamine use patterns. As of 2024, no direct pharmacokinetic data are available for 2F-NENDCK; all information is inferred from structural analogies to ketamine and limited user reports.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a> Based on these analogies, oral administration is expected to exhibit low bioavailability due to extensive first-pass hepatic metabolism, while intranasal and intramuscular routes likely achieve higher absorption. Onset of effects is anticipated to vary by route, potentially similar to ketamine (e.g., 5-30 minutes for intranasal or intramuscular).<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>Metabolism of 2F-NENDCK is expected to occur primarily in the liver through cytochrome P450 enzymes, though specific isoforms remain unidentified. The main biotransformation pathway is presumed to involve N-dealkylation, yielding an active metabolite analogous to norketamine (e.g., 2-fluorodeschloro-norketamine), as seen in ketamine metabolism via CYP3A4 and CYP2B6. Additional minor metabolites may include hydroxylated and glucuronidated forms, with structural modifications like fluorine substitution potentially altering metabolic rates compared to ketamine. The elimination half-life is unknown but may be similar to ketamine's 2-3 hours based on arylcyclohexylamine analogs.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>Total duration of effects is reported by users to last 4-6 hours, exceeding ketamine's typical 1-hour insufflated duration, with aftereffects persisting up to 12 hours.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a> Excretion is expected to occur mainly via renal and biliary routes, primarily as conjugated metabolites, though exact proportions are unknown. In toxicological screening, 2F-NENDCK and its metabolites are detectable in urine and blood using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS), with persistence estimated at 24-48 hours post-administration, depending on dose and individual factors; hair analysis may extend detection windows for chronic exposure. The lack of direct data underscores uncertainties in potency, toxicity, and interactions, particularly given its detection in illicit samples as of 2024.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a><a href="https://grokipedia.com/page/2f_nendck#ref-2"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-2">[2]</a>

Effects and Uses​

Subjective Effects​

The subjective effects of 2F-NENDCK, a novel arylcyclohexylamine dissociative, are primarily reported through anecdotal user accounts from harm reduction communities, as formal clinical studies are lacking. These effects resemble those of ketamine but are often described as more intense and prolonged, with a faster onset, stronger visual distortions, and greater disorientation, attributed to its presumed NMDA receptor antagonism.<a
Users report mild euphoria in some instances, often accompanying a stimulating body high that can lead to increased energy and prolonged wakefulness.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a> Dissociation from the body and mind is a core positive experience, sometimes escalating to a "k-hole"-like state of complete numbness and detachment, described as more immersive than with ketamine.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a> Strong visual distortions, including colorful hallucinations, contribute to a recreational appeal, with some noting serotonergic qualities enhancing the sensory experience.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>

Neutral Effects​

Dissociation manifests as a separation of mind from body, often without deep introspection or emotional warmth seen in ketamine.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a> Time dilation and cognitive disorientation are common, impairing memory and spatial awareness during the experience.<a href="https://grokipedia.com/page/2f_nendck#ref-3"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-3">[3]</a> Sedation varies, with some users feeling energized rather than heavily sedated.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>

Negative Effects​

Anxiety and paranoia can emerge, particularly during intense dissociation, alongside loss of motor control leading to coordination difficulties or falls.<a href="https://grokipedia.com/page/2f_nendck#ref-3"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-3">[3]</a> Nausea is frequently reported, sometimes accompanied by vomiting, and a pronounced hangover with fatigue persists into the next day.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a> At higher doses, delirium-like states with vivid auditory hallucinations and total loss of consciousness may occur, increasing risks of injury.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>Effects are highly dose-dependent, with low doses (starting below typical ketamine amounts of 20-175 mg, often as small "bumps" due to greater potency) producing stimulation and mild dissociation, while higher doses (undocumented but risking overdose) induce full "holing" with anesthesia-like immobility.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a><a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a> Compared to 2F-DCK, 2F-NENDCK is reported as more recreational and stimulating; relative to ketamine or MXE analogs, it offers less euphoria but stronger, quicker-plateauing intoxication.<a href="https://grokipedia.com/page/2f_nendck#ref-13"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-13">[13]</a>The total duration is typically 4-6 hours, longer than ketamine's profile, with a rapid onset (faster than ketamine) peaking within the first 1-2 hours and lingering aftereffects.<a href="https://grokipedia.com/page/2f_nendck#ref-14"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-14">[14]</a><a href="https://grokipedia.com/page/2f_nendck#ref-3"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-3">[3]</a>As a novel substance first identified in 2022, 2F-NENDCK has no documented therapeutic research or approved medical uses.<a href="https://grokipedia.com/page/2f_nendck#ref-1"><sup></sup></a><a href="https://grokipedia.com/page/2f_nendck#ref-1">[1]</a>
Why not just link a psychonautwiki article instead of copy+pasting grok-formatted AI generated pharmacological information?
 
Top